
Galderma has announced the launch of two phase 2 clinical trials evaluating its monoclonal antibody, nemolizumab, in two conditions: systemic …
ESTEVE CDMO adds $17.5m to Illinois expansion
Brenntag and dsm-firmenich expand biopharma vitamin partnership

